Drug intelligence / Profile preview

BACLOCALM

Development stage: Unknown
Lead developer: Labatec Pharma
Modality: Small Molecules
Administration: Oral

Overview

BACLOCALM is an oral formulation of baclofen, a centrally acting skeletal muscle relaxant. Marketed by Labatec Pharma, it is primarily used for the management of muscle spasticity associated with neurological conditions such as multiple sclerosis or spinal cord injuries, as well as other musculoskeletal disorders. Baclofen acts as an agonist at the gamma-aminobutyric acid type B (GABA-B) receptors in the spinal cord. By stimulating these receptors, it inhibits both monosynaptic and polysynaptic reflex transmission, which reduces the release of excitatory neurotransmitters. This mechanism leads to a decrease in muscle spasms, pain, and stiffness, improving motor function in patients with chronic spasticity.

Brand names: BACLOCALM
Other names: baclofen

Targets

GABA-B (Gamma-aminobutyric acid receptor type B)

Beyond the preview

Go deeper on BACLOCALM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BACLOCALM.

Explore the full profile